Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628504 | 0.81 | MEN1 (0.49) | MTORPIK3CAPIK3CG | |
| SCHEMBL629287 | 0.76 | MEN1 (0.51) | — | |
| SCHEMBL17527868 | 0.76 | MTOR (0.42) | MTORPIK3CAMAP3K12ATR | |
| SCHEMBL7876707 | 0.76 | ATR (0.37) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL628559 | 0.74 | MTOR (0.51) | MTORPIK3CAPIK3CGMAP3K12PIK3CD | |
| SCHEMBL628089 | 0.73 | PIK3CA (0.40) | MTORPIK3CAPIK3CGMAP3K12PIK3CD | |
| SCHEMBL30364648 | 0.72 | MTOR (0.47) | MTORPIK3CAPIK3CGMAP3K12PIK3CD | |
| SCHEMBL20692825 | 0.72 | MTOR (0.47) | MTORPIK3CAPIK3CGMAP3K12PIK3CD | |
| SCHEMBL628322 | 0.72 | KMT2A (0.54) | MTORPIK3CAPIK3CG | |
| SCHEMBL628557 | 0.71 | PIK3CA (0.39) | MTORPIK3CAPIK3CGMAP3K12PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.